Sign In
Buy CMPX
$2.10
+0.0200 (+0.96%)
At Close: Jun 03, 2026
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
10:31am, Friday, 04'th Oct 2024
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics to Participate in Upcoming Investor Events
08:00am, Tuesday, 03'rd Sep 2024
BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
08:00am, Wednesday, 07'th Aug 2024
BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's Why
01:00pm, Wednesday, 10'th Jul 2024
Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Compass Therapeutics: Pointing Right At Some Tough Cancers
03:14am, Thursday, 20'th Jun 2024
Compass Therapeutics is an oncology-focused biotech developing novel immunotherapies for solid tumors, with a focus on gastrointestinal cancers. Their most advanced candidate, CTX-009, targets DLL4 an
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
08:00am, Thursday, 30'th May 2024
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t
Compass Therapeutics Announces CEO Transition
04:10pm, Tuesday, 28'th May 2024
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
08:00am, Tuesday, 14'th May 2024
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
08:00am, Monday, 13'th May 2024
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
08:00am, Friday, 12'th Apr 2024
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
08:00am, Wednesday, 10'th Apr 2024
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to
3 Penny Stocks With the Power to 10X Your $1K Investment
04:00pm, Sunday, 24'th Mar 2024
Today we will be looking at three penny stocks with the power to 10x your $1K investment. The three firms discussed below have outsized potential to turn a small capital allocation into a much larger
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
09:00am, Thursday, 21'st Mar 2024
Enrollment in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), continues to progress well; top-line da
